Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from SOPHiA GENETICS ( (SOPH) ) is now available.
On January 12, 2026, SOPHiA GENETICS announced a planned leadership transition, promoting President Ross Muken to Chief Executive Officer effective July 1, 2026, succeeding co-founder and current CEO Dr. Jurgi Camblong, who is expected to move into the role of Executive Chairman of the Board following the company’s June 2026 annual general meeting. The company also released preliminary, unaudited financial figures for the fourth quarter and full year ended December 31, 2025, indicating at least $21 million in quarterly revenue, up about 20% year over year, and approximately $77 million in annual revenue, up about 18%, alongside record activity on its SOPHiA DDM platform with more than 391,000 analyses performed in 2025; these estimates underscore continued growth in usage and revenue but remain subject to adjustment as year-end closing and audit procedures are completed.
The most recent analyst rating on (SOPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
SOPHiA GENETICS’ overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. While technical analysis shows positive momentum, valuation concerns due to ongoing losses weigh heavily. The earnings call highlights strong growth and strategic initiatives, but these are not enough to offset the financial challenges.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS SA is a Switzerland-based health technology company that develops and commercializes data-driven medicine solutions, notably its SOPHiA DDM platform used for advanced data analyses in genomics and related clinical applications. The company focuses on enabling hospitals, laboratories and research institutions to leverage cloud-based analytics to interpret complex biomedical data at scale.
Average Trading Volume: 100,296
Technical Sentiment Signal: Buy
Current Market Cap: $336.5M
See more insights into SOPH stock on TipRanks’ Stock Analysis page.